# Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

> **NCT06153394** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Western University, Canada** · enrollment: 50 (estimated)

## Conditions studied

- Hepatic Disease
- Surgery-Complications
- Hypercoagulability
- Thrombosis

## Interventions

- **DRUG:** Redesca (enoxaparin sodium for injection)
- **DRUG:** Fragmin (dalteparin)

## Key facts

- **NCT ID:** NCT06153394
- **Lead sponsor:** Western University, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153394, "Prolonged Hypercoagulability Following Major Liver Resection for Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06153394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*